GPC yanks FDA application for satraplatin

Stymied by FDA regulators, GPC Biotech has pulled its application for satraplatin, an experimental therapy for prostate cancer. Regulators demanded to see more data on the drug before they could make a final decision, and GPC now plans to wait until a late-stage trial is complete before resubmitting. Data from the Phase III trial is expected in six months.

- read the report from Hemscott

Related Articles:
GPC cancer drug voted down by FDA committee. Report
FDA questions satraplatin. Report
Phase III data backs Satraplatin for prostate cancer. Report
GPC posts positive satraplatin data. Report
Pharmion signs $270M licensing deal for GPC's satraplatin. Report

Suggested Articles

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.